Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

The drug delivery system enables the release of the active pharmaceutical ingredient to
achieve a desired therapeutic response. Conventional drug delivery systems (tablets …

The past decades have witnessed great progress in cancer immunotherapy, which has
profoundly revolutionized oncology, whereas low patient response rates and potential …

Since the last few decades, the development of smart hydrogels, which can respond to
stimuli and adapt their responses based on external cues from their environments, has …

Malignant brain tumors, a heterogeneous group of primary and metastatic neoplasms in the
central nervous system (CNS), are notorious for their highly invasive and devastating …

The demand for biomaterials that promote the repair, replacement, or restoration of hard and
soft tissues continues to grow as the population ages. Traditionally, smart biomaterials have …

With the development of nanotechnology, nanomedicines are widely used in tumor therapy.
However, biological barriers in the delivery of nanoparticles still limit their application in …

Gene therapy provides a promising approach in treating cancers with high efficacy and
selectivity and few adverse effects. Currently, the development of functional vectors with …

The antitumor efficiency and clinical translation of traditional nanomedicines is mainly
restricted by low drug loading, complex preparation technology, and potential toxicity …

As immunogenic cell death (ICD) inducers initiating antitumor immune responses, certain
chemotherapeutic drugs have shown considerable potential to reverse the …